Mohamed Emam Sobeih, Council Member at European School of Oncology College, Consultant of Medical Oncology at NCI Egypt, Founder of ECOC, shared a post on LinkedIn:
“I’m truly proud to share that one of the most important papers in my academic journey has just been published in BMC Cancer.
Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study
Malignant pleural mesothelioma remains one of the most challenging thoracic malignancies, with limited treatment options after first-line therapy. In this randomized phase II study, we explored the role of Gemcitabine as a maintenance strategy, aiming to improve disease control and patient outcomes.
I am deeply grateful to my outstanding co-authors Prof. Ola Khorshid, Prof. Maha Helal, Prof. Maha Yahia whose collaboration and dedication made this work possible.
Special thanks to My Dearest Prof. Rabab Gaafar for all her continuous support in her life and after passing away.
Most importantly, I would like to thank our patients who inspire every step of our research journey.”
Title: Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study
Authores: Mohamed Emam Sobeih, Maha Helal, Maha Yahia and Ola Khorshid.
Read the full open-access article here.
Other articles featuring Mohamed Emam Sobeih on OncoDaily.
